Evidence-Based Oncology National Comprehensive Cancer Network, American Association of Clinical Urologists, and Large Urology Group Practice Association Endorse Biomarkers in Prostate Cancer
June 07, 2018
By Robert Finch, MS, CGC
Accurate prediction of the natural history of prostate cancer is necessary to avoid overtreatment, which increases the morbidity rate in men and is costly to the healthcare system. Biomarkers, or molecular testing of the prostate cancer tumor tissue, can more accurately predict the aggressiveness of prostate cancer and help physicians determine who needs definitive treatment and who can safely pursue active surveillance.